MMR II LIVE FACTS

The MMRV II LIVE (Measles, Mumps, Rubella) vaccine is made by manufacturer Merck.

This vaccine is intended for ages 12 months. - 6 years of age (2 doses is recommended) 


SYMPTOMS OF MMR:

1. Measles: fever, cough, runny nose, and red, watery eyes, commonly followed by a rash that covers the whole body

2. Mumps: fever, headache, muscle aches, tiredness, loss of appetite, swollen/tender salivary glands under the ears on one or both sides

3. Rubella: fever, sore throat, rash, headache, and eye irritation


TRANSMISSION:

1. Measles, Mumps and Rubella - Respiratory Droplets, Poor Hygiene


INGREDIENTS:

1. Chick Embryo Cell Culture - (CHICKEN EGGS)

2. WI-38 Human Diploid Lung Fibroblasts - (ABORTED FETAL KIDNEY CELLS FROM THE 1960's)

3. Vitamins

4. Amino Acids

5. Fetal bovine serum - (COW BLOOD)

6. Sucrose - (CORN OR BEET SUGAR)

7. Glutamate - (AMINO ACID)

8. Recombinant human albumin - (HUMAN BLOOD)

9. Neomycin - (ANTIBIOTICS)

10. Sorbitol - (SUGAR ALCOHOL)

11. Hydrolyzed gelatin - (COLLAGEN skin, bone, tissue of cattle, chicken, pig, fish)

12. Sodium phosphate - (INORGANIC SALT)

13. Sodium chloride - (SALT) 


YOU SHOULD NOT GET THIS VACCINATION IF:

1. Has any severe, life-threatening allergies

2. Is pregnant, or thinks she might be pregnant

3. Weakened immune system due to disease (such as cancer or HIV/AIDS) or medical treatments (chemotherapy).

‚4. Has a parent, brother, or sister with a history of immune system problems. ‚

5. Condition that makes them bruise/bleed easily. Recently had a blood transfusion or received blood products.

6. Has Tuberculosis. ‚

7. Has gotten any other vaccines in the past 4 weeks

6. Is not feeling well.


CONTRAINDICATIONS:

1. Hypersensitivity

2. Do not give M-M-R II to pregnant females; effects on fetal development are unknown. Pregnancy should be avoided 3 months following vaccination

3. Anaphylactic or anaphylactoid reactions to neomycin

4. Febrile respiratory illness or other active febrile infection.

5. Patients receiving immunosuppressive therapy

6. Individuals with blood dyscrasias, leukemia, lymphomas of any type, malignant neoplasms affecting the bone marrow or lymphatic systems.

7. Primary and acquired immunodeficiency states, including patients who are immunosuppressed in association with AIDS or other clinical manifestations of infection with human immunodeficiency viruses; cellular immune deficiencies; and hypogammaglobulinemia and dysgammaglobulinemic states.

8. Measles inclusion body encephalitis (MIBE), pneumonitis and death as a direct consequence of disseminated measles vaccine virus infection have been reported in immunocompromised individuals inadvertently vaccinated with measles-containing vaccine.

9. Individuals with a family history of congenital or hereditary immunodeficiency


WARNING:

1. Persons with a history of cerebral injury, individual/family history of convulsions, or any other condition in which stress due to fever should be avoided.

2. Hypersensitivity to Eggs Live measles vaccine and live mumps vaccine are produced in chick embryo cell culture.

3. history of anaphylactic/anaphylactoid, or immediate reactions (e.g., hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock)

4. A history of contact dermatitis to neomycin is not a contraindication to receiving measles vaccine.

5. Thrombocytopenia Individuals with current thrombocytopenia may develop more severe thrombocytopenia following vaccination. In addition, individuals who experienced thrombocytopenia with the first dose of M-M-R II (or its component vaccines) may develop thrombocytopenia with repeat doses.

6. Serologic status may be evaluated to determine whether or not additional doses of vaccine are needed. The potential risk to benefit ratio should be carefully evaluated before considering vaccination in such cases

7. M-M-R II has not been evaluated for carcinogenic (CANCER) or mutagenic potential (DNA MUTATION), or potential to impair fertility (INFERTILITY)